Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-01-02
2007-01-02
Lukton, David (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C530S331000, C548S517000
Reexamination Certificate
active
09912674
ABSTRACT:
This invention is directed to novel (substituted) acyl dipeptidyl ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the prevention of ischemic injury, and for the preservation of organs that are to undergo a transplantation procedure.
REFERENCES:
patent: 5585357 (1996-12-01), Dolle et al.
patent: 5656627 (1997-08-01), Bemis et al.
patent: 5714484 (1998-02-01), Zimmerman et al.
patent: 5919790 (1999-07-01), Allen et al.
patent: 6242422 (2001-06-01), Karanewsky et al.
patent: 761 680 (1997-03-01), None
patent: 623 606 (1998-01-01), None
patent: 644 197 (1998-09-01), None
patent: 623 592 (2001-06-01), None
patent: 2292149 (1996-02-01), None
patent: WO 93/09135 (1993-05-01), None
patent: WO 95/05192 (1995-02-01), None
patent: WO 96/30395 (1996-10-01), None
patent: WO 97/22618 (1997-06-01), None
patent: WO 99/47545 (1999-09-01), None
patent: WO 99/66945 (1999-12-01), None
Dolle et al., “Pyridazinodiazepines as a High-Affinity, P2-P3 Peptidomimetic Class of Interleukin-1β-Converting Enzyme Inhibitor,”J. Medicinal Chemistry 40(13):1941-1945, Jun. 20, 1997.
Semple et al., “Peptidomimetic Aminomethylene Ketone Inhibitors of Interleukin-1β-Converting Enzyme (ICE),”Bioorganic&Medicinal Chemistry Letters 8(8):959-964, Apr. 21, 1998.
Brennan, F.M et al., “Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures,”Clinical and Experimental Immunology 81: 278-285, 1990.
Frost, R.A. et al., “Lipopolysaccharide regulates proinflammatory cytokine expression in mouse myoblasts and skeletal muscle,”Am. J. Physiol. Regul. Interg. Comp. Physiol. 283: R698-R709, Sep. 2002.
Meyers, K.P. et al., “Effect of Treatment with Interleukin-1 Receptor Antagonist on the Development of Carrageenan-Induced Pleurisy in the Rat,”Inflammation 17(2): 121-134, Apr. 1993.
Paris, M.M. et al., “Effect of Interleukin-1 Receptor Antagonist and Soluble Tumor Necrosis Factor Receptor in Animal Models of Infection,”The Journal of Infectious Diseases 171(1): 161-169, Jan. 1995.
Read, S.J. et al., “Limiting Neurological Damage After Stroke. A Review of Pharmacological Treatment Options,”Drugs&Aging 14(1): 11-39, Jan. 1999.
Rosenbaum and Boney, “Activity of an Interleukin 1 Receptor Antagonist in Rabiit Models of Uveitis,”Archives of Opthalmology 110: 547-549, Apr. 1992.
Kalish Vincent J
Karanewsky Donald S
Robinson Edward D
Ullman Brett R
Idun Pharmaceuticals, Inc.
Lukton David
Seed IP Law Group PLLC
LandOfFree
(Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3721017